SCHEMBL24414535

SCHEMBL24414535

Cc1ccc(-c2ccc(-c3ccc(C)c(C(F)(F)F)c3)nc2)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP11B1 P15538 1/20 0.46
CYP11B2 P19099 1/20 0.46
AR P10275 1/20 0.44
CTSS P25774 1/20 0.42
CTSK P43235 1/20 0.42
PIK3CD O00329 1/20 0.42
NOTUM Q6P988 3/20 0.42
S1PR1 P21453 5/20 0.41
PDE3B Q13370 1/20 0.39
PDE3A Q14432 1/20 0.39
HSD17B1 P14061 1/20 0.37
HSD17B2 P37059 1/20 0.37
KDM1A O60341 2/20 0.36
CCR1 P32246 1/20 0.36
CCR5 P51681 1/20 0.36
CCR8 P51685 1/20 0.36
HDAC6 Q9UBN7 1/20 0.36
TRPV1 Q8NER1 1/20 0.36
DGAT1 O75907 1/20 0.35
AURKA O14965 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17297890 0.82 AR (0.61) CYP11B1CYP11B2ARCTSSCTSK
SCHEMBL19243109 0.77 CYP11B1 (0.50) CYP11B1CYP11B2CTSSCTSKPDE3B
SCHEMBL10000250 0.76 CCR1 (0.54) NOTUMHSD17B1HSD17B2KDM1ACCR1
SCHEMBL5949422 0.76 AR (0.52) ARCTSSCTSKNOTUMS1PR1
SCHEMBL4051545 0.76 NOTUM (0.44) CYP11B1CYP11B2ARPIK3CDNOTUM
SCHEMBL4404647 0.74 CCR1 (0.64) HSD17B1HSD17B2KDM1ACCR1CCR5
SCHEMBL5949403 0.74 NOTUM (0.53) ARCTSSCTSKNOTUMS1PR1
SCHEMBL30742956 0.74 NOTUM (0.53) ARCTSSCTSKNOTUMS1PR1
SCHEMBL30742957 0.74 NOTUM (0.53) ARCTSSCTSKNOTUMS1PR1
SCHEMBL21241437 0.74 S1PR1 (0.49) CYP11B1CYP11B2CTSSCTSKPIK3CD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220144850-A1 INDOLO HEPTAMYL OXIME ANALOGUE AS PARP INHIBITOR CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) 2022-05-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220144850-A1 INDOLO HEPTAMYL OXIME ANALOGUE AS PARP INHIBITOR PARP1, PARP2, PARP3 CYP11B1 1616/4885CYP11B2 1388/4885AR 1267/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.